Updates as of February 2, 2022:
With the predominance of the Omicron variant, National Institutes of Health (NIH) treatment recommendations, and recent data showing that bamlanivimab/etesevimab and casirivimab/imdevimab (REGEN-COV) are not effective against the Omicron variant, the FDA has revised the EUAs for these two monoclonal antibodies. Bamlanivimab/etesevimab and casirivimab/imdevimab (REGEN-COV) are currently not authorized for use in any U.S. states, territories, and jurisdictions.
With the rapid spread of the Omicron variant in mid-December 2021 and data showing that bamlanivimab/etesevimab is not effective in patients infected with this variant, the NIH updated their treatment guidelines to recommend against the use of bamlanivimab/etesevimab on January 19, 2022.
On January 24, 2022, the FDA revised the EUA for bamlanivimab/etesevimab to limit its use. Bamlanivimab/etesevimab is not authorized for use in any U.S. states, territories, and jurisdictions at this time.
HHS has paused allocation of bamlanivimab/etesevimab, and, at this time, CDPH is not distributing bamlanivimab/etesevimab to jursidictions. This product is not available and cannot be ordered.
If future variants are found to be susceptible to bamlanivimab/etesevimab, this product may become available in the future.
āOriginally published on March 9, 2021